ARCHIVES

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

Circulating Tumor Cells Predict Treatment Resistance In Study Of Metastatic Breast Cancer

August 30, 2013

Cancer Groups Endorse Richard Pazdur for Head of FDA’s New Office of Oncology Drug Products. Five Candidates Are In the Running for the Job, Sources Said.

February 18, 2005

NCI spends A Third Of Its Budget On Prevention

May 15, 1992

Panel Urges Research On DCIS To Identify Women At High Risk For Invasive Cancer

September 25, 2009

IOM Report Calls For FDA Authority Nutritional Supplement Health Claims

May 21, 2010

Siteman Wins Core Grant; Other Cancer Center News.

August 31, 2001